The DIRECTOR-GENERAL having regard to determination no. 20/2015 of January 19, 2015 concerning the medicinal product for human use SIMPONI (golimumab) published in the official journal-General series-# 22 of January 28, 2015; Considered the documentation to this Office;
Grinding in art. 3 (for the purpose of Classification) where it is written: for the therapeutic indications rheumatoid arthritis (RA), psoriatic arthritis (AP), ankylosing spondylitis (SA): rheumatologist; Read: therapeutic indications for rheumatoid arthritis (RA), psoriatic arthritis (AP), ankylosing spondylitis (SA): rheumatologist, internist;
Rome, February 11, 2015 Director General: Pani